Tirabrutinib clinical trials
Also written ONO-4059 and GS-4059.
How each study uses tirabrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tirabrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 1
Gilead Sciences (8) · Ono Pharmaceutical Co., Ltd. (5) · Kyorin University (1)
Often tested with
Tested in the same studies.
Idelalisib (1) · Entospletinib (1) · Lanraplenib (1) · GLPG0634 (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test tirabrutinib, phase 3 first.
- Sep 2027ONO-4059 Study in Patients With Steroid-resistant PemphigusPhase 3 · Ono Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses tirabrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingPhase 3Ono Pharmaceutical Co., Ltd.NCT07104032Written as Tirabrutinib
- Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)RecruitingPhase 2Kyorin UniversityNCT06940791Written as Tirabrutinib
- Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSLActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT06541665Written as ONO-4059
- ONO-4059 Study in Patients With Steroid-resistant PemphigusActive, not recruitingPhase 3Ono Pharmaceutical Co., Ltd.NCT06696716Written as ONO-4059
- A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsCompletedPhase 1Ono Pharmaceutical Co., Ltd.NCT07198087Written as Tirabrutinib
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)Active, not recruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT04947319Written as Tirabrutinib
- Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesTerminatedPhase 1Gilead SciencesNCT02457598Written as Tirabrutinib
- Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1Gilead SciencesNCT02457559Written as Tirabrutinib
- Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2Gilead SciencesNCT02968563Written as Tirabrutinib
- Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2Gilead SciencesNCT02983617Written as Tirabrutinib
- Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous UrticariaWithdrawnPhase 2Gilead SciencesNCT04827589Written as Tirabrutinib
- Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLCompletedPhase 1Gilead SciencesNCT01659255Written as Tirabrutinib
- Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeCompletedPhase 2Gilead SciencesNCT03100942Written as Tirabrutinib
- Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)CompletedPhase 1Gilead SciencesNCT02626026Written as Tirabrutinib
Codes
What other systems call tirabrutinib · ClinicalTrials.gg INT000477
- MeSH (NLM) C000608238tirabrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LXG44NDL2TTIRABRUTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27283239tirabrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102876TirabrutinibOne source FDA
- DrugBank DB15227One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608238 | tirabrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LXG44NDL2T | TIRABRUTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27283239 | tirabrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102876 | Tirabrutinib | One source FDA |
| DrugBank | DB15227 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.